STAT+: Civica Rx begins selling its first outpatient generic drug as it tries to overhaul the pharmaceutical supply chain

“I love it whenever another high cost generic product can be knocked down a peg," said Alex Oshmyanksy of the Mark Cuban Cost Plus Drugs Company.

In the latest bid to address high prescription drug costs, a nonprofit plans to sell a cheaper generic version of an expensive cancer medicine in the U.S.

Civica Rx, which was formed four years ago, is working with a generic manufacturer, Hikma Pharmaceuticals, to supply pharmacies with the abiraterone prostate cancer treatment for $160 for a month’s supply. And the nonprofit is suggesting pharmacies sell the medicine to consumers for $171, which is considerably less than what most consumers currently pay. The brand-name version is Zytiga.

Continue to STAT+ to read the full story…